POSEIDA THERAPEUTICS INC.
Company Snapshot
Company Overview
Founded as a spin out of Transposagen Biopharmaceuticals, Poseida Therapeutics Inc. is developing gene editing technologies for a range of human diseases. The company is focusing on lentiviral vector-based gene therapy and CAR-T product candidates for liver disorders and cancer, respectively.
Poseida’s platform utilizes the piggyBac transposon system, which enables footprint-free gene editing. The platform uses both positive and negative selection to achieve very high-purity gene-edited products. Other platforms include TAL-Clover and Cas-Clover site-specific nucleases, and Footprint-Free Gene Editing.
P-BCMA-101, a CAR-T therapy candidate, is in Phase I clinical development for treating multiple myeloma. In December 2021, the company was granted FDA approval for P-MUC1C-ALLO1 which is a CAR-T product for targeting multiple solid tumors. In October 2021, Poseida Therapeutics Inc. collaborated with Takeda Pharmaceutical for the development of novel non-viral in vivo gene therapies.
POSEIDA THERAPEUTICS INC. In Reports
POSEIDA THERAPEUTICS INC. In News
Company's Business Segments
- Products : PiggyBac Platform, Cas-CLOVER Platform, Leading Gene Delivery Systems, TSCM Cells
- Services : Collaborations, Research and Development, Others
Applications/End User Industries
- Biotechnology
- Pharmaceuticals
- Healthcare
- Research and Academics
